Remy and Datarocx
We're delighted to announce a strategic licensing agreement with Datarocx Inc., marking a substantial stride forward in expanding our market presence and revenue streams. This partnership empowers us to harness our intellectual property, particularly in advanced delivery technologies of medicinal compounds across key international markets, collectively representing nearly 50% of the world's population.
​
The terms of our agreement grant Datarocx exclusive rights to utilize our intellectual property for the development, manufacture, and sale of Remy Biosciences Biodermal Technology™ patches and sublingual pills in territories spanning Pakistan, India, the Middle East, and the entire African continent. This collaboration not only widens our global footprint but also secures a sustainable revenue stream through royalties.
Datarocx Inc. stands as a pillar of innovation, boasting substantial achievements and global partnerships. Their credibility stands out with established agreements poised to unlock millions in potential funding from both public and private sources, paving the way for significant future growth and innovation.
​
The strategic licensing agreement grants Datarocx exclusive rights to utilize Remy Biosciences' proprietary technology for the development, manufacture, and sale of Biodermal patches and sublingual pills in key territories spanning Pakistan, India, the Middle East, and North Africa. These regions collectively represent nearly 50% of the global population and are among the fastest-growing economic regions globally.
​
Embarking on this transformative journey, Remy Biosciences and Datarocx Inc. are committed to delivering innovative healthcare solutions that make a meaningful impact on global health.